Literature DB >> 35611264

A Phase 2 Clinical Trial of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma.

.   

Abstract

Entities:  

Year:  2021        PMID： 35611264      PMCID： PMC9122050     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.

Authors:  David E Gerber; Alison T Stopeck; Lucas Wong; Lee S Rosen; Philip E Thorpe; Joseph S Shan; Nuhad K Ibrahim
Journal:  Clin Cancer Res       Date:  2011-10-11       Impact factor: 12.531

2.  A Phase 2 Clinical Trial of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

3.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 4.  Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.

Authors:  Olivier Belzile; Xianming Huang; Jian Gong; Jay Carlson; Alan J Schroit; Rolf A Brekken; Bruce D Freimark
Journal:  Immunotargets Ther       Date:  2018-01-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.